Please assess the completion status of the following clinical trial:

Trial Title: REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 55 years~* HBsAg \> 1000 IU / ml~* HDAg+~* HDV RNA +~* No detectable antibodies to HIV, HCV or CMV.~* Non cirrhotic~* Willingness to utilize adequate contraception while being treated with REP 213-Ca and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~* Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 25 kg/m2~Exclusion Criteria:~* Evidence of cardiovascular disease~* Evidence of autoimmune hepatitis~* Presence of Wilson's disease~* Presence of severe NAFLD~* Evidence of any other co-existent liver disease~* ANA (anti-nuclear antibody) positive~* Fibroscan and Fibromax showing evidence of advanced cirrhosis.~* Any history of ascites, hepatic encephalopathy or variceal hemorrhage~* Body weight \> 100 kg~* Platelet count \< 90,000, PMN count \< 1,500 or HCT \< 33%~* Evidence of significant heavy metal load in whole blood.~* AFP \> 100 ng/ml or the presence of a hepatic mass suggestive of HCC~* Bilirubin above the normal range~* ALT \> 5x ULN~* Creatinine \> 1.5 mg/dl~* Serum albumin \< 35 mg/ml~* The presence of diabetes (whether controlled or uncontrolled)~* Another serious medical disorder~* A serious psychiatric disorder~* Evidence of hypertension~* A history of alcohol abuse within the last year~* The use of illicit drugs within the past two years~* Inability to provide informed consent~* Inability or unwillingness to provide weekly blood samples~* Poor venous access making IV infusion too difficult~* Patient not willing to come every week to receive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- REP 2139-Ca + Pegasys (TM) (Type: EXPERIMENTAL): REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).